Newer treatments for diabetes mellitus: A caveat with rapid glycaemic improvement and caution regarding changes in retinopathy screening guidelines within the UK NHS programme

Abstract

Keywords

diabetic retinopathy semaglutide GLP-1 receptor agonists glycaemic control worsening

Get full access to this article

View all access options for this article.

References

Varughese

Jacob

Existing and emerging GLP-1 receptor agonist therapy: Ramifications for diabetic retinopathy screening. J R Coll Physicians Edinb. Epub ahead of Print 05 April 2024. DOI: 10.1177/14782715241244843

Varadhan

Humphreys

Hariman

, et al. GLP-1 agonist treatment: implications for diabetic retinopathy screening. Diabetes Res Clin Pract 2011; 94: 68.

Marso

Bain

Consoli

, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834–1844.

Sabanayagam

Banu

Chee

, et al. Incidence and progression of diabetic retinopathy: a systematic review. Lancet Diabetes Endocrinol 2019; 7: 140–149.

Jacob

Varughese

GI.

Enhancing glycaemic control with impetus on weight management: Observing for early worsening of diabetic retinopathy. Eye (Lond) Epub ahead of Print 10 February 2024. DOI: 10.1038/s41433-024-02980-y

Frias

Davies

Rosenstock

, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021; 385: 503–515.